FDA OKs expanded use of Corifact

03/4/2013 | American City Business Journals

The FDA has approved the use of Corifact to address surgical bleeding in children and adults with inherited factor XIII deficiency. The drug has been approved since 2011 for use in routine preventive treatment for patients with the congenital deficiency.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN